UAE grants ImmunityBio's Anktiva broad approval for bladder and lung cancer

IBRX ImmunityBio Inc

$6.74 -5.13%

View chart & analysis →

1. 1ImmunityBio (IBRX) shares rose about 8% Wednesday night after the UAE approved Anktiva for broad use in bladder and metastatic lung cancer
2. 2For bladder, the approval covers the full range of BCG-unresponsive cases including papillary-only disease; for lung, it targets metastatic non-small cell lung cancer that has progressed after standard treatment
3. 3The UAE became the first in the world to open the full bladder indication, while the US decision on the papillary-only expansion is targeted for January 6, 2027

Source Stocktwits +8 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →